Skip to main content
SpringerLink
Log in

Inotuzumab ozogamicin

Acute cholecystitis: case report

  • Case report
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Khouri IF, et al. Safety of addition of inotuzumab ozogamicin (CMC 544) to bendamustine, fludarabine, and rituximab (BFR) allogeneic conditioning for lymphoid malignancies. Blood 130 (Suppl. 1): 3240, 2017. Available from: URL: http://www.bloodjournal.org/content/130/Suppl_1/3240 [abstract] -USA

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Inotuzumab ozogamicin. Reactions Weekly 1695, 221 (2018). https://doi.org/10.1007/s40278-018-44048-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-018-44048-0

Search

Navigation